Pediatrics
Showing 1-9 of 9 Results
-
Sneha Ramakrishna
Assistant Professor of Pediatrics (Hematology/Oncology)
BioSneha Ramakrishna obtained her B. A. from the University of Chicago and her M.D. from the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. In medical school, through the Howard Hughes Medical Research Scholar Award, she joined Dr. Crystal Mackall’s laboratory, where she designed and developed various GD2 CAR-Ts and tested them in preclinical models. During her residency training in Pediatrics at the Children’s Hospital of Philadelphia, she cared for some of the first patients treated with CD19 CAR T cells, learning the power of this therapy first-hand. During her fellowship in Pediatric Hematology/Oncology at the Johns Hopkins/National Cancer Institute combined program, she worked with Dr. Terry Fry. She evaluated the mechanism of CD22 CAR T cell relapse in patients by developing an antigen escape model and establishing a deeper understanding of the effects of antigen density on CAR-T phenotype, expansion, and persistence (Fry…Ramakrishna…Mackall Nat Med, 2018; Ramakrishna, et al., Clinical Cancer Research, 2019). Since arriving at Stanford, Dr. Ramakrishna leads an interdisciplinary team that designs, develops, and successfully implements a robust correlative science platform for our novel CAR-T therapies. Analyzing patient samples from our first-in-human GD2 CAR-T trial (NCT04196413) treating a universally fatal cancer, diffuse midline glioma (DMG), we identified that intracerebroventricular CAR-T administration correlates with enhanced pro-inflammatory cytokines and reduced immunosuppressive cell populations in cerebrospinal fluid as compared to intravenous CAR-T administration (Majzner*, Ramakrishna*, et al., Nature 2022 *co-first authors). Her research program evaluates unique sets of patient samples using novel single-cell immune profiling to identify the drivers of CAR-T success or failure. Building on these findings, her team assesses approaches to enhance CAR-T efficacy and translate these findings to the clinic.
Clinically, Dr. Ramakrishna cares for children with solid tumors and treats hematologic, solid, and brain tumor pediatric patients with CAR T cell therapies in the Cancer Cellular Therapies program. -
Brian Richter
Associate Director of Division Operations, Pediatrics - Hematology/Oncology
Current Role at StanfordAssociate Director of Division Operations, Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation, & Regenerative Medicine
-
Raheleh Roudi
Life Science Research Professional 2, Pediatrics - Hematology/Oncology
BioRaheleh Roudi is a research scientist in the Department of Radiology at Stanford University. Dr. Roudi trained at the Iran University of Medical Sciences, Iran. She worked as an Assistant Professor at the Iran University of Medical Sciences, Iran from 2015 to 2019, before coming to the United States. During this time, Dr. Roudi worked on several projects which have led to successful collaborations with the Karolinska Institute; Charite Universitatsmedizin Berlin; Oslo University Hospital; National University of Singapore; Shanghai University of Traditional Chinese Medicine and University of Brescia, among other internationally recognized institutions.
Dr. Roudi was a visiting scientist in the University of Texas at San Antonio and then appointed as a postdoctoral associate at the University of Minnesota for one year, before joining Stanford University in 2022.
Her research interest focuses on the molecular oncology and immunotherapies of solid tumors and she published more than 40 peer reviewed papers. -
Katherine Jane Ryan
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
Clinical Assistant Professor (By courtesy), Adult NeurologyCurrent Research and Scholarly InterestsDr. Katherine “Katie” Ryan is a pediatric neuro-oncologist whose research focuses on developing and translating cellular immunotherapies for children with malignant brain tumors. She leads the first-in-human trial of GPC2-directed CAR T cells for CNS Embryonal Tumors. As a member of Stanford Children’s world-renowned pediatric brain tumor team, she diagnoses and treats children with CNS tumors while advancing innovative trial design, intracerebroventricular delivery, and correlative science.
